# ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart Failure

> **NCT00610051** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Biopeutics Co., Ltd** · enrollment: 600 (estimated)

## Conditions studied

- End Stage Cardiac Failure
- HFrEF - Heart Failure With Reduced Ejection Fraction
- NYHF Class III-IV

## Interventions

- **DRUG:** Alprostadil

## Key facts

- **NCT ID:** NCT00610051
- **Lead sponsor:** Biopeutics Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2029-11
- **Final completion:** 2030-12
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00610051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00610051, "ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart Failure". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00610051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*